Bausch Health Companies Inc. (BHC) Expands Hepatology Portfolio with DURECT Acquisition

We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Bausch Health Companies Inc. is one of them.

Bausch Health Companies Inc. (NYSE:BHC) is a global specialty pharmaceutical and medical device company focused on eye health, gastroenterology, neurology, and dermatology.

In Q2 2025, Bausch Health Companies Inc. (NYSE:BHC) reported strong operational results, with revenues of $2.53 billion, up 5.3% year-over-year, and net income surging 1,380% from the same quarter in 2024. Earnings per share rose to $0.40, surpassing analyst expectations. This performance reflects successful debt reduction initiatives, including plans to repay $900 million via senior notes redemption and loan repayments, strengthening the firm’s financial position.

Bausch Health Companies Inc. (NYSE:BHC) is also expanding its pipeline and portfolio through strategic acquisitions. The recent acquisition of DURECT Corporation enhances its hepatology segment with a focus on liver disease therapies, signaling a shift toward higher-growth therapeutic areas.

Investor sentiment has been positively influenced by an FDA breakthrough designation, boosting share performance amid market volatility.

While we acknowledge the potential of BHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.